Amicus Therapeutics, Inc.
FOLD
$14.38
$0.010.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.05% | 21.28% | 25.35% | 28.25% | 32.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.05% | 21.28% | 25.35% | 28.25% | 32.29% |
| Cost of Revenue | 37.75% | 23.85% | 19.38% | 16.21% | 41.84% |
| Gross Profit | 18.08% | 20.99% | 26.02% | 29.65% | 31.30% |
| SG&A Expenses | 18.59% | 15.03% | 13.66% | 13.08% | 17.48% |
| Depreciation & Amortization | -12.72% | -12.48% | -9.67% | -6.16% | 8.56% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.34% | 17.72% | 13.52% | 2.93% | 4.52% |
| Operating Income | 1.25% | 139.68% | 198.51% | 182.70% | 146.35% |
| Income Before Tax | 100.66% | 107.29% | 77.46% | 97.71% | 80.84% |
| Income Tax Expenses | -0.18% | -47.59% | -20.85% | 295.93% | 1,744.23% |
| Earnings from Continuing Operations | 51.68% | 86.57% | 68.13% | 80.03% | 62.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.68% | 86.57% | 68.13% | 80.03% | 62.99% |
| EBIT | 1.25% | 139.68% | 198.51% | 182.70% | 146.35% |
| EBITDA | -1.55% | 82.42% | 297.50% | 214.29% | 164.94% |
| EPS Basic | 52.51% | 86.85% | 68.84% | 80.49% | 63.97% |
| Normalized Basic EPS | 109.09% | 114.41% | 78.10% | 100.04% | 85.55% |
| EPS Diluted | 51.43% | 85.96% | 68.06% | 79.86% | 63.37% |
| Normalized Diluted EPS | 108.11% | 113.98% | 78.10% | 100.04% | 85.55% |
| Average Basic Shares Outstanding | 1.31% | 1.52% | 1.96% | 2.53% | 3.13% |
| Average Diluted Shares Outstanding | 1.47% | 1.69% | 1.96% | 2.53% | 3.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |